Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis

Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study)

Tsutomu Takeuchi, Yoshiya Tanaka, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Takahiko Kurasawa, Satoshi Kubo, Kazuyoshi Saito, Kumi Shidara, Noriko Kimura, Hayato Nagasawa, Hideto Kameda, Koichi Amano, Hisashi Yamanaka

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.

Original languageEnglish
Pages (from-to)327-338
Number of pages12
JournalModern Rheumatology
Volume22
Issue number3
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

Rheumatoid Arthritis
Safety
Therapeutics
Methotrexate
Exercise
Adalimumab
Biological Products

Keywords

  • Adalimumab
  • Japanese
  • Radiographic outcome
  • Retrospective study
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis : Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study). / Takeuchi, Tsutomu; Tanaka, Yoshiya; Kaneko, Yuko; Tanaka, Eiichi; Hirata, Shintaro; Kurasawa, Takahiko; Kubo, Satoshi; Saito, Kazuyoshi; Shidara, Kumi; Kimura, Noriko; Nagasawa, Hayato; Kameda, Hideto; Amano, Koichi; Yamanaka, Hisashi.

In: Modern Rheumatology, Vol. 22, No. 3, 06.2012, p. 327-338.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Kaneko, Yuko ; Tanaka, Eiichi ; Hirata, Shintaro ; Kurasawa, Takahiko ; Kubo, Satoshi ; Saito, Kazuyoshi ; Shidara, Kumi ; Kimura, Noriko ; Nagasawa, Hayato ; Kameda, Hideto ; Amano, Koichi ; Yamanaka, Hisashi. / Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis : Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study). In: Modern Rheumatology. 2012 ; Vol. 22, No. 3. pp. 327-338.
@article{be4a5f42ee6a41d6ab681183545cd06c,
title = "Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study)",
abstract = "We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3{\%} achieved clinical remission: 42.4 and 28.6{\%} of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5{\%} of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8{\%} of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.",
keywords = "Adalimumab, Japanese, Radiographic outcome, Retrospective study, Rheumatoid arthritis",
author = "Tsutomu Takeuchi and Yoshiya Tanaka and Yuko Kaneko and Eiichi Tanaka and Shintaro Hirata and Takahiko Kurasawa and Satoshi Kubo and Kazuyoshi Saito and Kumi Shidara and Noriko Kimura and Hayato Nagasawa and Hideto Kameda and Koichi Amano and Hisashi Yamanaka",
year = "2012",
month = "6",
doi = "10.1007/s10165-011-0516-6",
language = "English",
volume = "22",
pages = "327--338",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis

T2 - Retrospective analyses of data collectedduring the first year of adalimumab treatment in routine clinical practice (HARMONY study)

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Kaneko, Yuko

AU - Tanaka, Eiichi

AU - Hirata, Shintaro

AU - Kurasawa, Takahiko

AU - Kubo, Satoshi

AU - Saito, Kazuyoshi

AU - Shidara, Kumi

AU - Kimura, Noriko

AU - Nagasawa, Hayato

AU - Kameda, Hideto

AU - Amano, Koichi

AU - Yamanaka, Hisashi

PY - 2012/6

Y1 - 2012/6

N2 - We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.

AB - We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinicaland functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P\0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.

KW - Adalimumab

KW - Japanese

KW - Radiographic outcome

KW - Retrospective study

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84865372548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865372548&partnerID=8YFLogxK

U2 - 10.1007/s10165-011-0516-6

DO - 10.1007/s10165-011-0516-6

M3 - Article

VL - 22

SP - 327

EP - 338

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -